Skip to content
DataLookout
Menu

NCT05988372

Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

StatusUnknown
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting
  2. Minor Interventions: Albumin-paclitaxel + Gemcitabine (Drug), Sulfatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine (Drug) to Albumin-paclitaxel + Gemcitabine (Drug), Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine (Drug)
    • Study description revised
    • Study title revised
    v4
  3. Notable Start date: Aug 30, 2023 to Oct 23, 2023v3 Show 8 more changesShow less
    • Enrollment target: 42 to 50
    • Primary completion date: Aug 30, 2023 to Oct 23, 2023
    • Study completion date: Aug 30, 2026 to Oct 23, 2026
    • Interventions: Albumin-paclitaxel (Drug), Gemcitabine (Drug), Serplulimab (Drug), Sulfatinib (Drug) to Albumin-paclitaxel + Gemcitabine (Drug), Sulfatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine (Drug)
    • Secondary endpoints: 6 to 7
    • Study description expanded, about 178 words
    • Study arms: 1 to 2
    • Study title shortened, about 1 word
  4. Minor Study title expanded, about 5 wordsv2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

R0 Surgical Resection Rate
Timeframe: Up to 2 years

Secondary (7)

Surgical conversion rate
Objective response rate (ORR)
Deepness of response (DpR)
Progression-Free Survival (PFS)
Disease-free survival (DFS)
Show 2 moreShow less
Over Survival (OS)
Quality of Life (QOL)

Arms and interventions

Surufatinib + Serplulimab+Albumin-paclitaxel + GemcitabineExperimental

enrolled, eligible patients receive Surufatinib, Serplulimab, Gemcitabine and Albumin-paclitaxel

Albumin-paclitaxel + GemcitabineExperimental

enrolled, eligible patients receive Gemcitabine and Albumin-paclitaxel

Drugs: Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine, Albumin-paclitaxel + Gemcitabine

Sites

1 site in 1 country

  • First Affiliated Hospital, Sun Yat-Sen UniversityGuangzhou, Guangdong, China